Inve India ▾

Prevest Denpro share price & results

Prevest Denpro Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Jammu-based manufacturer of dental materials and equipment (restorative, endodontic, prosthodontic, preventive, orthodontic), sold via dealers and agents across 90+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue19.1 ₹ crore+20.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin35.5 %+1.8 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit5.6 ₹ crore+27.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity18.81 %−1.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin18.21 %−2.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)14.78 %+1.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 5 judged targets kept · 6 open · verdicts reflect calls analysed to Q4 FY26.

Prevest Denpro Limited management guidance track record on Inve: 11 targets tracked across analysed earnings calls (4 achieved, 1 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
New Product LaunchesLaunch at least 4 to 5 new products in the 2025-2026 fiscal year
Call transcript, Q4 FY25 · 30 May 2025		Q4 FY25Q4 FY26:Management confirmed commercialization of disinfectants and Rotoflex during the year, and R&D updates mentioned 2 new products hitting the market, meeting the lower end of the target range.
Call transcript, Q4 FY26 · 29 Jun 2026		Achieved
H2 Revenue GrowthExpect to cross 20% in the next half year
Call transcript, Q2 FY26 · 20 Nov 2025		Q2 FY26Q4 FY26:Calculated H2 FY26 revenue growth was approximately 12% YoY, falling short of the >20% guidance, which management attributed to geopolitical tensions and supply chain disruptions in Q4.
Call transcript, Q4 FY26 · 29 Jun 2026		Missed
Digital Dentistry Business GrowthReach to a better level in 2026
Call transcript, Q4 FY25 · 30 May 2025		Q4 FY25Q4 FY26:Reported significant growth with 3D printer sales up 162% and 3D resins up 40.5% YoY. Capacity utilization for new products (including digital) is now at 18-20%. This demonstrates reaching a 'better level'.
Call transcript, Q4 FY26 · 29 Jun 2026		On Track

Source: Inve Guidance Tracker for Prevest Denpro Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Prevest Denpro Limited's 11 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 8 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹379 +0.01% · +₹0.05

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −28.3% 1Y

₹350₹400₹450₹500₹550Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 20 Nov 2025Q4 FY26 — 29 Jun 2026

1Y: ₹528.65 on 24 Oct 2025 → ₹379. High ₹540 (27 Oct 2025), low ₹341.8 (30 Mar 2026).

Previous close
₹378.95
Market cap
₹485 Cr
52-week range
₹341.8 – ₹540
One year
−29.81%
Price to earnings (TTM to Jun 2026)
22.33×
Return on equity (TTM to Jun 2026)
18.81%

Overview

Symbol
NSE:PREVEST
Exchange
NSE
Currency
INR

What Prevest Denpro Limited does

Based on the company's own presentations, annual report and earnings calls.

Prevest DenPro makes dental materials and equipment covering restorative, endodontic, prosthodontic, preventive, aesthetic and orthodontic categories, manufactured at its Jammu facilities. It sells through a network of domestic dealers and overseas agents (B2B) as well as a direct-to-consumer online store, and runs an in-house R&D centre (Prevest Research Centre) for new-product development. It has recently added digital-dentistry offerings (3D-printed resins, printers, scanners) and a disinfectant-products line, and operates a US subsidiary, Axiodent Inc.

Segments

  • Dental materials
  • Dental equipment
  • Digital dentistry / 3D printing
  • Disinfectant products
Product portfolio
100+ dental materials/products
Manufacturing units
2 (Jammu, J&K)
Export reach
90+ countries
Dealer network (India)
60+
Overseas agents
90+
Total employees
250 (as of Mar-25)
Founded 1999Headquarters Jammu, IndiaEmployees 250 (FY25) Company website

How the price took the results

close before → close after

Q4 FY26
−2.1%
29 Jun
Q2 FY26
−1.0%
20 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Prevest Denpro Limited

Free account: one company. Everything above stays public.

Write why you follow Prevest Denpro Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Prevest Denpro Limited

Guides on how to read this kind of business and the numbers that matter.